Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

OBJECTIVE: To assess pooled golimumab safety up to year 3 of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) trials. METHODS: Golimumab 50 and 100 mg, administered subcutaneously (SC) every 4 weeks (q4wk), were assessed in patients with active RA (methotrexate-na...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Rheum Dis
Autors principals: Kay, Jonathan, Fleischmann, Roy, Keystone, Edward, Hsia, Elizabeth C, Hsu, Benjamin, Mack, Michael, Goldstein, Neil, Braun, Jürgen, Kavanaugh, Arthur
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2015
Matèries:
Clinical and Epidemiological Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4345908/
https://ncbi.nlm.nih.gov/pubmed/24344160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2013-204195
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars